ClinicalTrials.gg
Not yet recruitingNCT07890584Updated Oct 22, 2026

A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

A Phase 3 interventional study of PLS240 and Standard of Care in Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism, sponsored by Pathalys Pharma. Not yet recruiting at 1 site in United States. Open to participants aged 1 Month to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Pathalys Pharma · Phase 3, Interventional, and Treatment

Updated Oct 22, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
1 Month to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 218 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Planned enrollment
456th of 819
56 · median 72
Started
2026
with 43 others
Phase 3
147 of 988
13 open now
Primary completion
2032-02
later than 212 of 216 live
Registered
981st of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 456th largest by planned enrollment of the 819 interventional ones that give a count, is one of 44 that started in 2026, is one of 147 in phase 3, reaches primary completion later than 212 of the 216 other live ones, and was the 981st registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

165 more — sign in →

All 170 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 1 Month to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

Approximately 56 participants who are 1 month old to 17 years old will be enrolled in this study. The total duration for this study will be 38 weeks (or up to 42 weeks when participants require a washout period due to prior exposure to prohibited medications) and includes the following periods:

  • Active screening period of 6 weeks (or, up to 10 weeks for participants requiring a washout period).
  • Treatment period of 28 weeks consisting of a 19-week dose titration period and 9-week stable dose period.
  • Safety follow-up period of 4 weeks.
03

Conditions studied

  • Chronic Kidney Disease (CKD)
  • Secondary Hyperparathyroidism

Keywords

  • Chronic Kidney Disease (CKD)
04

Who can participate

Ages eligible
1 Month to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants age of >1 month to \<18 years (Cohort 1: ≥13 to \<18 years, Cohort 2: >1 month to \<13 years).
  2. Dry weight ≥7 kg during screening.
  3. Diagnosed with Chronic Kidney Disease (CKD) and secondary hyperparathyroidism (SHPT) undergoing maintenance hemodialysis at the time of screening.

Exclusion criteria

Exclusion Criteria:

  1. History of congenital long syndrome, second- or third-degree heart block, ventricular tachyarrhythmias, or other conditions associated with prolonged QT interval.
  2. Anticipated parathyroidectomy during the study period.
  3. Scheduled kidney transplant during the study period.
  4. Participants received a parathyroidectomy within 6 months prior to randomization.
  5. Receipt of cinacalcet therapy within 4 weeks prior to screening assessments and through randomization.
  6. Receipt of etelcalcetide within 6 months prior to screening assessments and through randomization.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Adolescents aged ≥13 to \<18 years. The study will initially only recruit participants into the older age group (Cohort 1). Participants will receive PLS240 plus standard of care.

    Drug: PLS240 · Combination Product: Standard of Care

  • Experimental
    Cohort 2

    Children aged 1 month to \<13 years. Once safety and Pharmacokinetic (PK)/Pharmacodynamic (PD) data from 15 evaluable participants from Cohort 1 have been reviewed by a Safety Review Committee (SRC), recruitment into the younger (infants, toddlers, and children) age group will commence. Participants will receive PLS240 plus standard of care.

    Drug: PLS240 · Combination Product: Standard of Care

  • Active comparator
    Control Group

    Participants will only receive standard of care

    Combination Product: Standard of Care

Interventions

  • DrugPLS240

    Intravenous (IV) bolus injection three times a week (TIW)

    Also known as: upacicalcet

  • Combination productStandard of Care

    Active vitamin D sterols, calcium supplementation, and/or phosphate binders

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs).

    Time frame: From the first dialysis session after randomization and up to 28 days after the last administration of study medication for participants receiving PLS240 and up to Week 32 for participants in the control group.

Secondary outcomes

  1. Change from baseline in intact parathyroid hormone (iPTH) over time

    Time frame: Baseline through the End of Study visit [Study Week 32 + 7 days]

  2. Concentration of upacicalcet in plasma at Weeks 2, 16, and 26.

    Time frame: Week 2 (post-dialysis/pre-dose and 10 to 30 minutes post-dose), Week 16 (pre-dialysis and post-dialysis/pre-dose), and Week 26 (post-dialysis/pre-dose, and 10 to 30 minutes post-dose).

  3. Removal rate of upacicalcet by dialysis

    Time frame: Week 16 (pre-dialysis and post-dialysis/pre-dose)

07

Study locations

1 site
  • Site # 10103
    Buffalo, New York 14203, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Feb 2032, 63 months later.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's planned 63 months is above that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2026
First posted
Oct 22, 2026
StartEst.
Oct 30, 2026
Primary completionEst.
Feb 22, 2032
CompletionEst.
Feb 22, 2032
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07890584
Lead sponsor
Pathalys Pharma
Responsible party
Sponsor
First posted
Oct 22, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Feb 22, 2032 (estimated)
Completion
Feb 22, 2032 (estimated)
Last update
Oct 22, 2026

Study contacts

Pathalys Clinical Trials
Contact
clinicaltrials@pathalys.com
Please reach out by email

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upacicalcet sodium hydrate

Start the discussion